BLI-489

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H10N3O4S.Na
Molecular Weight	327.291
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[H][C@]12SC=C(N1C(=O)\C2=C\C3=CN4CCOCC4=N3)C([O-])=O

InChI

InChIKey=RFSWVJXWZXQOSW-ZDFSRXSCSA-M

InChI=1S/C13H11N3O4S.Na/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-15-1-2-20-5-10(15)14-7;/h3-4,6,12H,1-2,5H2,(H,18,19);/q;+1/p-1/b8-3-;/t12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H10N3O4S
Molecular Weight	304.301
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009

BLI 489 was developed by Wyeth as a 6-methylidene-penem β-lactamase inhibitor for the treatment of bacterial infections and urinary tract infections. BLI-489 has shown the promising clinical data, however, development of this drug, was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.	2009 Feb	19001109
Relationship between β-lactamase production and resistance phenotype in Klebsiella pneumoniae strains.	2017 Jul 6	28591808

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:49 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:49 GMT 2023`
Record UNII	R56JYB8P8Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BLI-489

Common Name

English

BLI 489

Code

English

4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-((5,6-DIHYDRO-8H-IMIDAZO(2,1-C)(1,4)OXAZIN-2-YL)METHYLENE)-7-OXO-, SODIUM SALT (1:1), (5R,6Z)-

Common Name

English

Code System Code Type Description

FDA UNII

R56JYB8P8Z

Created by admin on Fri Dec 15 16:04:49 GMT 2023 , Edited by admin on Fri Dec 15 16:04:49 GMT 2023

PRIMARY

PUBCHEM

23697683

Created by admin on Fri Dec 15 16:04:49 GMT 2023 , Edited by admin on Fri Dec 15 16:04:49 GMT 2023

PRIMARY

CAS

623564-40-9

Created by admin on Fri Dec 15 16:04:49 GMT 2023 , Edited by admin on Fri Dec 15 16:04:49 GMT 2023

PRIMARY

Related Record Type Details


					156B510BCG

BLI-489 FREE ACID

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

DescriptionSources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009

Originator

Approval Year

PubMed

Sample Use Guides

Description
Sources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009